Our priority is to develop an inhaled treatment for idiopathic pulmonary fibrosis (IPF), a chronic interstitial lung disease, characterised by excessive scarring of the lungs. IPF is invariably fatal, with median survival rates of between two and four years following diagnosis.
Expression of the αvβ6 integrin is elevated in fibrotic lung tissue compared to healthy tissue, supporting its status as a therapeutic target. Subsequently, we will develop Alevin’s pipeline to address other unmet medical needs including chronic kidney disease (CKD), acute kidney injury (AKI) and cancer.
Highlights from the Scientific Founders’ Publications
Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease. European Journal of Pharmacology, 2021.
Late-stage functionalization via Chan-Lam amination: rapid access to potent and selective integrin inhibitors. Chemistry A European Journal, 2020.
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020.
Structure activity relationships αv Integrin antagonists for pulmonary fibrosis by variation in arylsubstituents. ACS Medicinal Chemistry Letters, 2014.
For an expanded list of relevant publications from the Scientific Founders, please click here.